Intravesical Disitamab Vedotin (RC48) for HER2‐Expressing High‐Risk Non‐Muscle‐Invasive Bladder Cancer: A Single‐Arm, Dose–Escalation Phase I Trial Study

ABSTRACT HER2 expression is correlated with diminished efficacy of Bacillus Calmette–Guérin (BCG) instillation in high‐risk non‐muscle‐invasive bladder cancer (HR‐NMIBC). The development of effective intravesical treatments for HER2‐expressing HR‐NMIBC is of great urgency. In this single‐arm phase I...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	Xu Chen, Ming Huang, Zehua Chen, Chengjunyu Zhang, Bolin Pan, Chu Liu, Wentong Xu, Jianmin Fang, Jian Huang, Tianxin Lin
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	Wiley 2025-07-01
Cyfres:	MedComm
Pynciau:	antibody‒drug conjugates (ADC) Disitamab vedotin (RC48) efficacy intravesical non‐muscle‐invasive bladder cancer safety
Mynediad Ar-lein:	https://doi.org/10.1002/mco2.70288
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!